Prevention of Vaccinia Lesions in Rhesus Monkeys by Human Leucocyte and Fibroblast Interferon Free

Abstract

SUMMARY

The prophylactic antiviral activity of systemically administered human interferon preparations was tested in 36 rhesus monkeys against vaccinia virus injected into the skin. All nine control monkeys developed typical vaccinia skin lesions. Eight of nine monkeys treated with daily intramuscular injections of leucocyte interferon (5 × 10 units/kg) from day -1 to day +7 after vaccination were completely protected. No lesions developed after discontinuation of therapy, Administration of the same amounts of leucocyte interferon intravenously (i.v.) was equally effective. Daily intramuscular (i.m.) injections of lower doses of leucocyte interferon (1.25 × 10 units/kg; 0.5 × 10 units/kg) decreased the severity of the skin lesions. Lesion scores correlated inversely with the dose of interferon. Four of six animals receiving daily i.m. injections of fibroblast interferon (5 × 10 units/kg) and one of three animals treated i.v. with the same dose were protected against vaccinia virus, and the lesions in the other monkeys were smaller. Intramuscular injections of 5 × 10 units/kg of fibroblast interferon or 1.25 × 10 units/kg of leucocyte interferon resulted in comparable serum levels and had comparable efficacy in reducing lesion scores.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-48-1-25
1980-05-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/48/1/JV0480010025.html?itemId=/content/journal/jgv/10.1099/0022-1317-48-1-25&mimeType=html&fmt=ahah

References

  1. Andrews R. D. 1961; Specificity of interferon. British Medical Journal 1:1728–1730
    [Google Scholar]
  2. Arvin A. M., Feldman S., Merigan T. C. 1978; Human leukocyte interferon in the treatment of varicella in children with cancer: a preliminary controlled trial. Antimicrobial Agents and Chemotherapy 13:605–607
    [Google Scholar]
  3. Billiau A., Van Damme J., Van Leuven F., Edy V. G., De ley M., Cassiman J.-J., Van Den Berghe H, de somer P. 1979; Human fibroblast interferon for clinical trials: production, partial purification and characterization. Antimicrobial Agents and Chemotherapy 16:49–55
    [Google Scholar]
  4. Cantell K., Hirvonen S., Mogensen K. E., Pyhala L. 1974; Human leukocyte interferon: production, purification, stability, and animal experiments. In In Vitro, Proceedings of a Tissue Culture Association Workshop, 1973 pp 35–38 Edited by Waymouth C. Rockville, Md.: Tissue Culture Association;
    [Google Scholar]
  5. Cheeseman S. H., Rubin R. H., Stewart J. A., Tolkoff-Rubin N. E., Cosimi A. B., Cantell K., Gilbert J., Winkle S., Herrin J. T., Black P. H., Russell P. S., Hirsch M. S. 1979; Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. New England Journal of Medicine 300:1345–1349
    [Google Scholar]
  6. Dunnick J. K., Oalasso O. J. 1979; Clinical trials with exogenous interferon: summary of a meeting. Journal of Infectious Diseases 139:109–123
    [Google Scholar]
  7. Edy V. O., Billiau A., De Somer P. 1976; Human fibroblast and leucocyte interferons show different dose-response curves in assay of cell protection. Journal of General Virology 31:251–255
    [Google Scholar]
  8. Edy V. G., Billiau A., De Somer P. 1978; Non-appearance of injected fibroblast interferon in circulation. Lancet 1:451–452
    [Google Scholar]
  9. Finter N. B. 1969; Dye uptake methods for assessing viral cytopathogenicity and their application to interferon assays. Journal of General Virology 5:419–427
    [Google Scholar]
  10. Hekker A. C., Bos J. M., Smith L. 1973; A stable freeze-dried smallpox vaccine made in monolayer cultures of primary rabbit kidney cells. Journal of Biological Standardization 1:21–32
    [Google Scholar]
  11. Merigan T. C., Rand K. H., Pollard R. B., Abdallah P. S., Jordan G. W., Fried R. P. 1978; Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. New England Journal of Medicine 298:981–987
    [Google Scholar]
  12. Pinto C. A., Haff R. F., Valenta J. R., Pagano J. F., Dicuollo C. J., Ferlauto R. J. 1969; Human interferon. II. Biological activity. In Symposia Series in Immunobiological Standardization vol 14 pp 105–112 Basel: S. Karger;
    [Google Scholar]
  13. Schellekens H., Weimar W., Cantell K., Stitz L. 1979; Antiviral effect of interferon in vivo may be mediated by the host. Nature, London 278:742
    [Google Scholar]
  14. Scientific Committee On Interferon 1970; Progress towards trials of human interferon in man. Annals of the New York Academy of Sciences 173:770–781
    [Google Scholar]
  15. Strander H., Cantell R., Carlstrom G., Ingimarsson S., Jakobsson P., Nilsonne U. 1976; Acute infections in interferon-treated patients with osteosarcoma: preliminary report of a comparative study. Journal of Infectious Diseases 133: (suppl.) A245–A248
    [Google Scholar]
  16. Sundmacher R., Cantell K., Skoda R., Hallermann C., Neumann-Haefelin D. 1978; Human leukocyte and fibroblast interferon in a combination therapy of dendritic keratitis. Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie 208:229–233
    [Google Scholar]
  17. Weimar W., Schellekens H., Lameijer L. D. F., Masurel N., Edy V. G., Billiau A., De Somer P. 1978; Double-blind study of interferon administration in renal transplant recipients. European Journal of Clinical Investigation 8:255–258
    [Google Scholar]
  18. Weimar W., Heijtink R. A., Schalm S. W., Schellekens H. 1979; Differential effects of fibroblast and leucocyte interferon in HBsAg positive chronic active hepatitis. European Journal of Clinical Investigation 9:151–154
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-48-1-25
Loading
/content/journal/jgv/10.1099/0022-1317-48-1-25
Loading

Data & Media loading...

Most cited Most Cited RSS feed